Does combined used of Pentoxifylline and Tocotrienol help patients with thin endometrium

Not Applicable

• Conditions: Health Condition 1: O090- Supervision of pregnancy with history of infertility

• Registration Number: CTRI/2023/10/058640
• Lead Sponsor: Indira IVF Hospital Private Limited

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 16 October 2023

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

(a) History of one cancelled embryo transfer due to thin endo <7mm (after all conventional treatment as per institutional protocol.

(b) Age 25–45 years,

(c) Body mass index (BMI) 18.5 to 29.9 kg/m2

(d) Recipients of Donor oocyte & Donor embryo.

Exclusion Criteria

(a) Presence of uncontrolled endocrine disorders (uncontrolled diabetes mellitus/ hyperprolactinemia, thyroid dysfunction,

(b) Previous major uterine surgery

(c) Previous hysteroscopic surgery

(d) Adenomyosis

(e) Endometriosis

(f) Untreated hydrosalpinx

(g) RIF

(h) Cotreatment with any Nitric Oxide donor

(i) Patients with bleeding disorder or those who are at increased risk of retinal bleeding, peptic ulcer, or preoperative patients

(j) Patients with Renal Impairment: Patients with creatinine clearance less than 30 mL/min

(k) Allergy to xanthine derivatives, e.g., caffeine, theophylline, theobromine

(l) Acute myocardial infarction or severe coronary disease due to increased risk of myocardial demand

(m) Severe liver disease (Child pugh class C) or cirrhosis

(n) Pregnancy and Breastfeeding

(o) bleeding disorders (altered prothrombin time

(p) Co-administration with

(q) other antihypertensive drugs

(r) Glibenclamide or metformin

(s) other theophylline derivatives

(t) Co- treatment with Aspirin

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Endometrial thicknessTimepoint: before day 14-day 21 of HRT

Secondary Outcome Measures

Name	Time	Method
Biochemical PregnancyTimepoint: 14 days after embryo transfer;Clinical PregnancyTimepoint: 4 weeks after embryo transfer;Ongoing pregnancyTimepoint: 18 wks after embryo transfer plus 2 wks.